GSA Capital Partners’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$700K Sell
7,274
-3,860
-35% -$386K 0.04% 705
2025
Q4
$1.08M Sell
11,134
-2,651
-19% -$227K 0.09% 319
2025
Q3
$981K Buy
13,785
+2,351
+21% +$157K 0.08% 415
2025
Q2
$684K Buy
11,434
+6,253
+121% +$343K 0.05% 708
2025
Q1
$272K Buy
5,181
+1,075
+26% +$60.4K 0.02% 1218
2024
Q4
$226K Sell
4,106
-4,412
-52% -$232K 0.02% 1357
2024
Q3
$428K Sell
8,518
-2,302
-21% -$106K 0.03% 1017
2024
Q2
$475K Buy
10,820
+3,119
+41% +$133K 0.03% 1000
2024
Q1
$339K Buy
+7,701
New +$340K 0.03% 1138
2019
Q3
Sell
-11,301
Closed -$231K 1545
2019
Q2
$231K Sell
11,301
-2,595
-19% -$61.1K 0.03% 1167
2019
Q1
$390K Buy
13,896
+2,100
+18% +$55K 0.04% 837
2018
Q4
$289K Buy
11,796
+1,500
+15% +$40.3K 0.03% 857
2018
Q3
$382K Buy
+10,296
New +$278K 0.02% 1208
2016
Q3
Sell
-9,902
Closed -$215K 1847
2016
Q2
$215K Sell
9,902
-26,330
-73% -$474K 0.01% 1537
2016
Q1
$694K Sell
36,232
-13,971
-28% -$267K 0.04% 782
2015
Q4
$1.41M Buy
50,203
+31,901
+174% +$902K 0.07% 460
2015
Q3
$446K Buy
+18,302
New +$438K 0.02% 1187

Other funds holding IRMD

GSA Capital Partners's IRMD Position: Q1 2026 in Review

GSA Capital Partners reduced its iRadimed (IRMD) stake by 35% in Q1 2026, selling an estimated $386K and leaving 7,274 shares worth $700K. The position accounts for 0.04% of the portfolio, ranked #705.

GSA Capital Partners first reported a position in IRMD in Q3 2015 and has held it in 17 quarters since. The position peaked at $1.41M in Q4 2015. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • GSA Capital Partners held 7,274 shares of iRadimed worth $700K as of Q1 2026.
  • GSA Capital Partners sold 3,860 iRadimed shares in Q1 2026, an estimated $386K.
  • iRadimed made up 0.04% of GSA Capital Partners's portfolio in Q1 2026, its #705 holding.
  • GSA Capital Partners first reported a position in iRadimed in Q3 2015 and has held it in 17 quarters since.
  • GSA Capital Partners's iRadimed position peaked at $1.41M in Q4 2015.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.